Identification/NN
of/IN
a/DT
Copy/NN
Number/NN
Variation/NN
on/IN
Chromosome/NN
20q13.12/NN
Associated/VBN
with/IN
Osteoporotic/JJ
Fractures/NNS
in/IN
the/DT
Korean/JJ
Population/NN
./.
====================
Osteoporotic/JJ
fractures/NNS
(/(
OFs/NNS
)/)
are/VBP
critical/JJ
hard/VBP
outcomes/NNS
of/IN
osteoporosis/NN
and/CC
are/VBP
characterized/VBN
by/IN
decreased/VBN
bone/NN
strength/NN
induced/VBD
by/IN
low/JJ
bone/NN
density/NN
and/CC
microarchitectural/JJ
deterioration/NN
in/IN
bone/NN
tissue/NN
./.
====================
Most/JJS
OFs/NNS
cause/VBP
acute/JJ
pain/JJ
,/,
hospitalization/NN
,/,
immobilization/NN
,/,
and/CC
slow/JJ
recovery/NN
in/IN
patients/NNS
and/CC
are/VBP
associated/VBN
with/IN
increased/VBN
mortality/NN
./.
====================
A/DT
variety/NN
of/IN
genetic/JJ
studies/NNS
have/VBP
suggested/VBN
associations/NNS
of/IN
genetic/JJ
variants/NNS
with/IN
the/DT
risk/NN
of/IN
OF/IN
./.
====================
Genome-wide/NN
association/NN
studies/NNS
have/VBP
reported/VBN
various/JJ
single-nucleotide/JJ
polymorphisms/NNS
and/CC
copy/NN
number/NN
variations/NNS
(/(
CNVs/NNS
)/)
in/IN
European/JJ
and/CC
Asian/JJ
populations/NNS
./.
====================
To/TO
identify/VB
CNV/NN
regions/NNS
associated/VBN
with/IN
OF/IN
risk/NN
,/,
we/PRP
conducted/VBD
a/DT
genome-wide/NN
CNV/NN
study/NN
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
We/PRP
performed/VBD
logistic/JJ
regression/NN
analyses/NNS
in/IN
1,537/CD
Korean/JJ
subjects/NNS
(/(
299/CD
OF/IN
cases/NNS
and/CC
1,238/NN
healthy/JJ
controls/NNS
)/)
and/CC
identified/VBD
a/DT
total/JJ
of/IN
8/CD
CNV/NN
regions/NNS
significantly/RB
associated/VBN
with/IN
OF/IN
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
Then/RB
,/,
one/CD
CNV/NN
region/NN
located/JJ
on/IN
chromosome/NN
20q13.12/NN
was/VBD
selected/VBN
for/IN
experimental/JJ
validation/NN
./.
====================
The/DT
selected/VBN
CNV/NN
region/NN
was/VBD
experimentally/RB
validated/JJ
by/IN
quantitative/JJ
polymerase/NN
chain/NN
reaction/NN
./.
====================
The/DT
CNV/NN
region/NN
of/IN
chromosome/NN
20q13.12/NN
is/VBZ
positioned/VBN
upstream/RB
of/IN
a/DT
family/NN
of/IN
long/JJ
non-coding/JJ
RNAs/NNS
,/,
LINC01260/NN
./.
====================
Our/PRP$
findings/NNS
could/MD
provide/VB
new/JJ
information/NN
on/IN
the/DT
genetic/JJ
factors/NNS
associated/VBN
with/IN
the/DT
risk/NN
of/IN
OF/IN
./.
====================
Osteoporotic/JJ
fractures/NNS
(/(
OFs/NNS
)/)
result/NN
from/IN
a/DT
decrease/NN
in/IN
bone/NN
strength/NN
,/,
which/WDT
can/MD
be/VB
induced/VBN
by/IN
low/JJ
bone/NN
mass/NN
and/CC
microarchitectural/JJ
deterioration/NN
in/IN
bone/NN
tissue/NN
[/(
1/CD
]/)
./.
====================
OFs/NNS
are/VBP
the/DT
critical/JJ
hard/VBP
outcome/NN
of/IN
osteoporosis/NN
,/,
a/DT
disease/NN
that/DT
affects/VBZ
more/RBR
than/IN
75/CD
million/NN
people/NN
in/IN
the/DT
United/JJ
States/NNS
,/,
Europe/NN
,/,
and/CC
Japan/NNP
./.
====================
With/IN
a/DT
lifetime/JJ
fracture/NN
risk/NN
of/IN
30/CD
%/NN
to/TO
40/CD
%/NN
(/(
vertebral/JJ
or/CC
non-vertebral/JJ
fractures/NNS
)/)
,/,
osteoporosis/NN
has/VBZ
an/DT
incidence/NN
rate/NN
similar/JJ
to/TO
that/DT
of/IN
coronary/JJ
artery/NN
disease/NN
./.
====================
Furthermore/RB
,/,
with/IN
the/DT
exception/NN
of/IN
forearm/NN
fractures/NNS
,/,
OFs/NNS
are/VBP
associated/VBN
with/IN
increased/VBN
mortality/NN
./.
====================
Most/JJS
fractures/NNS
cause/VBP
acute/JJ
pain/JJ
and/CC
lead/VBP
to/TO
patient/NN
hospitalization/NN
,/,
immobilization/NN
,/,
and/CC
slow/JJ
recovery/NN
[/(
234/CD
]/)
./.
====================
Genetic/JJ
studies/NNS
have/VBP
suggested/VBN
a/DT
correlation/NN
of/IN
genetic/JJ
variations/NNS
with/IN
OF/IN
and/CC
its/PRP$
related/JJ
traits/VBZ
./.
====================
First/RB
,/,
a/DT
candidate/NN
gene/NN
study/NN
has/VBZ
reported/VBN
that/IN
common/JJ
non-synonymous/JJ
variants/NNS
in/IN
low-density/JJ
lipoprotein/NN
receptor-related/JJ
protein/NN
5/CD
(/(
LRP5/NN
)/)
are/VBP
consistently/RB
associated/VBN
with/IN
bone/NN
mineral/JJ
density/NN
(/(
BMD/NN
)/)
and/CC
fracture/NN
risk/NN
[/(
5/CD
]/)
./.
====================
Furthermore/RB
,/,
meta-analyses/NNS
of/IN
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
have/VBP
identified/VBN
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
located/JJ
in/IN
more/RBR
than/IN
56/CD
loci/NNS
independently/RB
associated/VBN
with/IN
BMD/NN
,/,
and/CC
some/DT
of/IN
these/DT
studies/NNS
have/VBP
also/RB
found/VBD
associations/NNS
with/IN
fracture/NN
risk/NN
[/(
678910111213/CD
]/)
./.
====================
Copy/NN
number/NN
variations/NNS
(/(
CNVs/NNS
)/)
also/RB
have/VBP
shown/VBN
associations/NNS
with/IN
OF/IN
./.
====================
A/DT
genome-wide/JJ
CNV/NN
study/NN
performed/VBD
in/IN
a/DT
Chinese/JJ
population/NN
identified/VBD
a/DT
deletion/NN
variant/JJ
of/IN
UDP/NN
glucuronosyltransferase/NN
2/CD
family/NN
,/,
polypeptide/NN
B17/NN
(/(
UGT2B17/CD
)/)
in/IN
chromosome/NN
4q13.2/CD
associated/VBN
with/IN
OF/IN
[/(
14/CD
]/)
;/:
however/RB
,/,
this/DT
variant/JJ
was/VBD
not/RB
replicated/VBN
in/IN
a/DT
study/NN
of/IN
Caucasian/JJ
women/NNS
[/(
15/CD
]/)
,/,
possibly/RB
showing/VBG
ethnic/JJ
specificity/NN
./.
====================
Additionally/RB
,/,
a/DT
rare/JJ
deletion/NN
variant/JJ
located/JJ
on/IN
chromosome/NN
6p25.1/NN
showed/VBD
an/DT
association/NN
with/IN
the/DT
risk/NN
of/IN
OF/IN
in/IN
a/DT
Dutch/NN
population/NN
[/(
16/CD
]/)
./.
====================
Particularly/RB
,/,
chromosome/NN
20q13.12/NN
is/VBZ
known/VBN
as/IN
an/DT
enriched/JJ
region/NN
of/IN
histone/NN
modifications/NNS
./.
====================
Many/JJ
genes/NNS
located/JJ
on/IN
chromosome/NN
20q13.12/NN
have/VBP
enriched/VBN
levels/NNS
of/IN
histone/NN
modifications/NNS
,/,
such/JJ
as/IN
di-methylated/VBN
lysine/NN
4/CD
of/IN
histone/NN
3/CD
(/(
H3K4me2/NN
)/)
and/CC
tri-methylated/VBD
lysine/NN
4/CD
of/IN
histone/NN
3/CD
(/(
H3K4me3/NN
)/)
,/,
in/IN
their/PRP$
promoter/NN
regions/NNS
[/(
17/CD
]/)
./.
====================
H3K4me2/NN
and/CC
H3K4me3/NN
regulate/VBP
the/DT
expression/NN
of/IN
the/DT
Runx2/NN
gene/NN
,/,
which/WDT
encodes/VBZ
a/DT
transcription/NN
factor/NN
controlling/VBG
bone/NN
development/NN
and/CC
osteoblast/JJ
differentiation/NN
[/(
18/CD
]/)
./.
====================
Although/IN
there/EX
is/VBZ
no/DT
previous/JJ
study/NN
on/IN
an/DT
association/NN
between/IN
chromosome/NN
20q13.12/NN
and/CC
bone-related/JJ
traits/VBZ
,/,
an/DT
SNP/NN
in/IN
another/DT
20q/NN
region/NN
(/(
rs4811196/CD
in/IN
CTNBL1/NN
,/,
located/JJ
on/IN
20q11.23/NN
)/)
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
BMD/NN
[/(
19/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
conducted/VBD
an/DT
association/NN
study/NN
in/IN
the/DT
Korean/JJ
population/NN
to/TO
identify/VB
new/JJ
susceptibility/NN
loci/NNS
for/IN
the/DT
risk/NN
of/IN
OF/IN
./.
====================
We/PRP
identified/VBD
8/CD
CNV/NN
regions/NNS
associated/VBN
with/IN
the/DT
risk/NN
of/IN
OF/IN
through/IN
a/DT
statistical/JJ
analysis/NN
./.
====================
Among/IN
the/DT
8/CD
regions/NNS
,/,
we/PRP
selected/VBD
and/CC
validated/VBD
the/DT
existence/NN
of/IN
one/CD
CNV/NN
by/IN
quantitative/JJ
PCR/NN
./.
====================
Study/NN
subjects/NNS
and/CC
diagnostic/JJ
criteria/NNS
for/IN
OF/IN
====================
A/DT
total/JJ
of/IN
10,038/CD
participants/NNS
from/IN
the/DT
Korea/NN
Association/NN
Resource/NN
(/(
KARE/NN
)/)
were/VBD
recruited/VBN
./.
====================
Among/IN
the/DT
recruited/VBN
individuals/NNS
,/,
1,537/CD
subjects/NNS
,/,
consisting/VBG
of/IN
299/CD
OF/IN
cases/NNS
and/CC
1,238/NN
normal/JJ
controls/NNS
,/,
who/WP
agreed/RB
to/TO
an/DT
X-ray/NN
examination/NN
were/VBD
genotyped/VBN
with/IN
the/DT
NimbleGen/NN
HD2/NN
3/CD
×/NN
720K/NN
comparative/JJ
genomic/JJ
hybridization/NN
array/NN
(/(
aCGH/JJ
)/)
./.
====================
This/DT
study/NN
was/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
the/DT
Korea/NN
Centers/NNS
for/IN
Disease/NN
Control/NN
and/CC
Prevention/NN
,/,
and/CC
written/RB
informed/VBN
consent/NN
was/VBD
provided/VBN
to/TO
all/DT
participants/NNS
,/,
including/VBG
cases/NNS
and/CC
controls/VBZ
./.
====================
The/DT
clinical/JJ
characteristics/NNS
of/IN
the/DT
study/NN
participants/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
We/PRP
used/VBD
low/JJ
trauma/NN
fracture/NN
events/NNS
to/TO
distinguish/VB
between/IN
fracture/NN
and/CC
non-fracture/JJ
groups/NNS
of/IN
the/DT
KARE/NN
study/NN
./.
====================
Fractures/NNS
were/VBD
only/RB
included/VBD
if/IN
they/PRP
had/VBD
occurred/VBD
with/IN
low/JJ
trauma/NN
(/(
e.g./FW
,/,
fall/DT
from/IN
standing/VBG
height/RB
or/CC
less/RBR
)/)
at/IN
any/DT
of/IN
six/CD
sites/NNS
(/(
hip/NN
,/,
wrist/RB
,/,
humerus/JJ
,/,
rib/NN
,/,
pelvis/FW
,/,
and/CC
vertebra/RB
)/)
after/IN
the/DT
age/NN
of/IN
40/CD
years/NNS
./.
====================
Fractures/NNS
clearly/RB
caused/VBD
by/IN
high/JJ
trauma/NN
events/NNS
(/(
e.g./FW
,/,
motor/NN
vehicle/NN
accidents/NNS
,/,
violence/RB
,/,
or/CC
falls/NNS
from/IN
more/RBR
than/IN
the/DT
standing/VBG
height/RB
of/IN
the/DT
individual/JJ
)/)
were/VBD
excluded/VBN
./.
====================
Platform/NN
of/IN
CNV/NN
genotyping/VBG
====================
We/PRP
used/VBD
the/DT
Roche/NN
NimbleGen/NN
3/CD
×/NN
720/CD
K/NN
aCGH/NN
platform/NN
for/IN
CNV/NN
calling/JJ
./.
====================
This/DT
platform/NN
was/VBD
designed/VBN
as/IN
a/DT
whole-genome/JJ
and/CC
CNV-focused/JJ
type/NN
,/,
composed/VBN
of/IN
a/DT
total/JJ
of/IN
720,000/CD
probes/NNS
./.
====================
The/DT
median/JJ
inter-probe/NN
spacing/NN
of/IN
the/DT
backbone/NN
was/VBD
</JJR
5/CD
kb/NN
./.
====================
DNA/NN
extracted/VBN
from/IN
the/DT
NA10851/NN
cell/NN
line/NN
was/VBD
utilized/VBN
as/IN
a/DT
reference/NN
for/IN
the/DT
aCGH/NN
to/TO
yield/VB
the/DT
signal/NN
intensity/NN
ratio/NN
with/IN
hg18/NCBI/NN
build/JJ
36/CD
./.
====================
All/DT
of/IN
the/DT
samples/NNS
in/IN
our/PRP$
study/NN
satisfied/VBD
experimental/JJ
control/NN
metrics/NNS
,/,
such/JJ
as/IN
chromosome/NN
X/NN
shift/NN
and/CC
mad.1dr/VBD
,/,
with/IN
NimbleScan/JJ
v.2.5/CD
to/TO
adapt/VB
systemic/JJ
biases/NNS
in/IN
the/DT
microarray/NN
experiment/NN
./.
====================
The/DT
signal/NN
intensity/NN
ratio/NN
of/IN
each/DT
probe/NN
was/VBD
converted/VBN
into/IN
log2/NN
scale/NN
with/IN
the/DT
positions/NNS
of/IN
the/DT
probes/NNS
after/IN
a/DT
quality/NN
control/NN
process/NN
./.
====================
CNV/NN
discovery/NN
====================
CNV/NN
discovery/NN
consisted/VBD
of/IN
two/CD
steps/NNS
:/:
CNV/NN
calling/JJ
and/CC
determination/NN
of/IN
the/DT
CNV/NN
region/NN
./.
====================
For/IN
CNV/NN
calling/JJ
,/,
we/PRP
used/VBD
a/DT
package/NN
,/,
called/VBN
“/NN
Genome/NN
Alteration/NN
Detection/NN
Analysis/NN
(/(
GADA/NN
)/)
,/,
”/NNP
which/WDT
implements/VBZ
a/DT
flexible/JJ
and/CC
efficient/JJ
pipeline/NN
to/TO
detect/VB
copy/NN
number/NN
alterations/NNS
from/IN
microarray/NN
data/NNS
[/(
20/CD
]/)
./.
====================
To/TO
avoid/VB
a/DT
limitation/NN
caused/VBD
in/IN
the/DT
single/JJ
detection/NN
tool/NN
,/,
we/PRP
found/VBD
the/DT
best/JJS
parameter/NN
(/(
T/NN
=/JJ
10/CD
,/,
alpha/NN
=/JJ
0.2/CD
,/,
and/CC
Min-SegLen/NN
=/JJ
10/CD
)/)
that/WDT
compared/VBN
a/DT
known/JJ
CNV/NN
region/NN
and/CC
CNVs/NNS
tested/VBN
using/VBG
several/JJ
parameters/NNS
[/(
21/CD
]/)
./.
====================
CNV/NN
was/VBD
employed/VBN
as/IN
the/DT
average/NN
log2/NN
ratio/NN
of/IN
±0.25/CD
of/IN
probes/NNS
in/IN
all/DT
individual/JJ
./.
====================
To/TO
estimate/VB
CNV/NN
genotypes/NNS
,/,
a/DT
CNV/NN
region/NN
was/VBD
defined/VBN
with/IN
a/DT
log2/NN
ratio/NN
identified/VBD
between/IN
the/DT
reference/NN
sample/NN
and/CC
test/VB
sample/NN
in/IN
the/DT
calling/JJ
process/NN
./.
====================
It/PRP
is/VBZ
hard/VBN
to/TO
define/VB
exact/JJ
genotype/NN
cluster/NN
of/IN
a/DT
CNV/NN
detected/VBN
in/IN
a/DT
single/JJ
individual/JJ
./.
====================
To/TO
discover/RB
CNV/NN
regions/NNS
,/,
we/PRP
employed/VBD
CNVs/NNS
that/DT
were/VBD
called/VBN
in/IN
over/IN
three/CD
individuals/NNS
[/(
22/CD
]/)
./.
====================
Genotype/NN
estimation/NN
====================
CNV/NN
genotypes/NNS
consist/VBP
of/IN
zero/CD
copies/NNS
,/,
one/CD
copy/NN
,/,
and/CC
two/CD
copies/NNS
./.
====================
To/TO
do/VBP
this/DT
,/,
we/PRP
used/VBD
an/DT
R/NN
package/NN
,/,
named/VBN
‘/NN
CNVtools/NNS
,/,
’/CD
with/IN
default/NN
parameters/NNS
to/TO
estimate/VB
CNV/NN
genotypes/NNS
[/(
23/CD
]/)
./.
====================
CNVtools/NNS
is/VBZ
a/DT
mixture/NN
model/NN
for/IN
one-dimensional/JJ
CNV/NN
data/NNS
summary/VBP
that/DT
can/MD
separate/VB
samples/NNS
into/IN
each/DT
CNV/NN
genotype/NN
./.
====================
To/TO
estimate/VB
genotype/NN
,/,
we/PRP
employed/VBD
the/DT
linear/JJ
discrimination/NN
function/NN
,/,
which/WDT
uses/VBZ
a/DT
raw/JJ
signal/NN
and/CC
pca/NN
signal/NN
calculated/JJ
from/IN
the/DT
average/NN
log2/NN
ratio/NN
of/IN
all/DT
individuals/NNS
using/VBG
CNVtools/NNS
./.
====================
CNV/NN
genotypes/NNS
consist/VBP
of/IN
three/CD
genotype/JJ
groups/NNS
:/:
“/CD
single-class/JJ
,/,
”/CD
“/CD
multiple-class/JJ
,/,
”/CD
and/CC
“/NN
ambiguous/JJ
”/CD
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
[/(
2425/CD
]/)
./.
====================
We/PRP
performed/VBD
an/DT
association/NN
study/NN
with/IN
only/RB
well-clustered/JJ
“/CD
multiple-class/JJ
”/CD
CNV/NN
regions/NNS
./.
====================
Statistical/JJ
analysis/NN
====================
Logistic/JJ
regression/NN
analysis/NN
was/VBD
performed/VBN
using/VBG
R/NN
package/NN
version/NN
3.0.2/CD
to/TO
find/VB
significant/JJ
association/NN
signals/NNS
between/IN
CNV/NN
loci/NNS
and/CC
OF/IN
risk/NN
./.
====================
Age/NN
,/,
height/RB
,/,
and/CC
weight/NN
were/VBD
adjusted/VBN
as/IN
covariates/VBZ
to/TO
calibrate/VB
the/DT
statistical/JJ
significance/NN
./.
====================
Genotypes/NNS
of/IN
each/DT
CNV/NN
were/VBD
coded/VBN
as/IN
0/CD
(/(
homozygous/JJ
deletion/NN
)/)
and/CC
1/CD
(/(
heterozygous/JJ
deletion/NN
)/)
for/IN
two-class/JJ
CNV/NN
loci/NNS
./.
====================
In/IN
the/DT
case/NN
of/IN
three-class/NN
CNVs/NNS
,/,
their/PRP$
genotypes/NNS
were/VBD
coded/VBN
as/IN
0/CD
(/(
homozygous/JJ
deletion/NN
)/)
,/,
1/CD
(/(
heterozygous/JJ
deletion/NN
)/)
,/,
and/CC
2/CD
(/(
normal/JJ
)/)
./.
====================
Validation/NN
of/IN
CNVs/NNS
====================
We/PRP
carried/VBD
out/RP
quantitative/JJ
PCR/NN
using/VBG
the/DT
TaqMan/NN
Copy/NN
Number/NN
Assay/NN
(/(
Life/NN
Technologies/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
protocols/NNS
to/TO
verify/VB
estimated/VBN
CNV/NN
regions/NNS
./.
====================
In/IN
total/JJ
,/,
seven/CD
pre-designed/JJ
and/CC
one/CD
custom/JJ
designed/VBN
probe/NN
was/VBD
used/VBN
to/TO
validate/VB
the/DT
existence/NN
of/IN
the/DT
CNV/NN
./.
====================
Validation/NN
samples/NNS
,/,
including/VBG
cases/NNS
and/CC
controls/VBZ
,/,
were/VBD
randomly/RB
selected/VBN
from/IN
each/DT
estimated/VBN
genotype/NN
cluster/NN
./.
====================
All/DT
validation/NN
experiments/NNS
were/VBD
replicated/VBN
3/CD
times/NNS
to/TO
increase/VB
the/DT
accuracy/NN
of/IN
the/DT
validation/NN
./.
====================
The/DT
copy/NN
number/NN
in/IN
each/DT
individual/JJ
was/VBD
calculated/VBN
with/IN
Copy/NN
Caller/NN
v2.0/CD
using/VBG
the/DT
comparative/JJ
threshold/NN
cycle/NN
(/(
CT/NN
)/)
method/NN
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
protocols/NNS
./.
====================
Characteristics/NNS
of/IN
study/NN
subjects/NNS
====================
A/DT
total/JJ
of/IN
1,537/CD
Korean/JJ
individuals/NNS
,/,
consisting/VBG
of/IN
299/CD
OF/IN
patients/NNS
and/CC
1,238/NN
normal/JJ
controls/NNS
,/,
participated/JJ
in/IN
this/DT
study/NN
(/(
Table/JJ
1/CD
)/)
./.
====================
There/EX
were/VBD
415/CD
males/NNS
and/CC
1,122/CD
females/NNS
in/IN
the/DT
overall/JJ
population/NN
./.
====================
The/DT
ratio/NN
of/IN
females/NNS
in/IN
controls/NNS
was/VBD
slightly/RB
higher/JJR
than/IN
in/IN
the/DT
cases/NNS
(/(
70/CD
%/NN
in/IN
cases/NNS
vs./CC
72/CD
%/NN
in/IN
controls/NNS
,/,
data/NNS
not/RB
shown/VBN
)/)
./.
====================
Mean/JJ
age/NN
,/,
height/RB
,/,
weight/NN
,/,
and/CC
body/NN
mass/NN
index/NN
showed/VBD
no/DT
significant/JJ
differences/NNS
between/IN
cases/NNS
and/CC
controls/VBZ
./.
====================
Selection/NN
of/IN
candidate/NN
CNV/NN
regions/NNS
====================
To/TO
select/VB
candidate/NN
CNV/NN
regions/NNS
,/,
we/PRP
manually/RB
performed/VBN
a/DT
visual/JJ
inspection/NN
to/TO
classify/VB
well-clustered/JJ
“/CD
multiple-class/JJ
”/CD
regions/NNS
into/IN
genotype/NN
groups/NNS
./.
====================
In/IN
total/JJ
,/,
3,660/CD
multiple-class/JJ
CNV/NN
regions/NNS
were/VBD
selected/VBN
for/IN
the/DT
association/NN
study/NN
./.
====================
Of/IN
the/DT
3,660/CD
CNV/NN
regions/NNS
,/,
518/CD
CNV/NN
regions/NNS
were/VBD
two-class/RB
regions/NNS
(/(
one/CD
and/CC
two/CD
copies/NNS
)/)
and/CC
3,142/CD
were/VBD
three-class/RB
regions/NNS
(/(
zero/CD
,/,
one/CD
,/,
and/CC
two/CD
copies/NNS
)/)
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Association/NN
analysis/NN
of/IN
CNV/NN
regions/NNS
with/IN
OF/IN
risk/NN
====================
We/PRP
performed/VBD
logistic/JJ
regression/NN
analysis/NN
to/TO
evaluate/VB
associations/NNS
between/IN
identified/VBN
CNV/NN
regions/NNS
and/CC
OF/IN
risk/NN
./.
====================
As/IN
a/DT
result/NN
,/,
we/PRP
identified/VBD
a/DT
total/JJ
of/IN
eight/CD
CNV/NN
loci/NNS
associated/VBN
with/IN
OF/IN
(/(
p/NN
</JJR
0.05/CD
)/)
(/(
Table/JJ
2/CD
)/)
—distributed/JJ
on/IN
chromosome/NN
4q13.1/NN
,/,
4q13.2/CD
,/,
9q34.2/CD
,/,
13q12.2/CD
,/,
14q24.3/CD
,/,
14q31.3/CD
,/,
20p13/NN
,/,
and/CC
20q13.12/NN
./.
====================
The/DT
OF-associated/JJ
loci/NNS
were/VBD
located/JJ
in/IN
intergenic/JJ
regions/NNS
near/JJ
SRIP1/NN
;/:
TMPRSS11E/NNP
;/:
POLR1D/NN
;/:
LOC-100421611/NN
;/:
a/DT
family/NN
of/IN
long/JJ
non-coding/JJ
RNAs/NNS
(/(
lncRNA/NN
)/)
,/,
LINC01260/NN
;/:
and/CC
genic/JJ
regions/NNS
of/IN
ABO/NN
,/,
ELMSAN1/NN
,/,
and/CC
SIRPA/NN
./.
====================
The/DT
base-pair/JJ
lengths/NNS
of/IN
the/DT
eight/CD
regions/NNS
ranged/VBD
from/IN
1.9/CD
kb/NN
to/TO
18.6/CD
kb/NN
./.
====================
The/DT
CNVs/NNS
in/IN
ABO/NN
and/CC
SIRPA/NN
included/VBD
both/CC
exonic/JJ
and/CC
intronic/JJ
regions/NNS
of/IN
each/DT
gene/NN
,/,
whereas/IN
the/DT
CNV/NN
locus/NN
in/IN
ELMSAN1/NN
included/VBD
only/RB
intronic/JJ
regions/NNS
./.
====================
Validation/NN
of/IN
a/DT
CNV/NN
region/NN
on/IN
chr20/NN
:/:
42739446–42741539/CD
====================
We/PRP
selected/VBD
one/CD
CNV/NN
region/NN
located/JJ
on/IN
chromosome/NN
20q13.12—chr20/CD
:/:
42739446–42741539—or/CD
validation/NN
based/VBN
on/IN
position/NN
and/CC
expected/VBN
biological/JJ
function/NN
./.
====================
The/DT
allele/NN
frequencies/NNS
of/IN
chr20/NN
:/:
42739446–42741539/CD
are/VBP
indicated/VBN
in/IN
Supplementary/JJ
Table/JJ
1/CD
and/CC
Supplementary/JJ
Fig/NN
./.
====================
2/CD
./.
====================
First/RB
,/,
we/PRP
conducted/VBD
in/IN
silico/NN
verification/NN
for/IN
the/DT
existence/NN
of/IN
the/DT
CNV/NN
region/NN
using/VBG
web-based/JJ
public/JJ
data/NNS
./.
====================
Many/JJ
previously/RB
reported/VBD
CNVs/NNS
,/,
including/VBG
the/DT
chr20/NN
:/:
42739446–42741539/CD
region/NN
,/,
were/VBD
identified/VBN
using/VBG
the/DT
UCSC/NN
Genome/NN
Browser/NN
(/(
http/NN
:/:
//genome.uscs.edu/cgi-bin/hgGateway/NN
)/)
(/(
Supplementary/JJ
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Also/RB
,/,
frequencies/NNS
of/IN
reported/VBN
CNVs/NNS
evaluated/VBD
in/IN
various/JJ
ethnic/JJ
groups/NNS
were/VBD
presented/VBN
in/IN
the/DT
Database/NN
of/IN
Genomic/JJ
Variants/NNS
(/(
DGV/NN
,/,
http/NN
:/:
//dgv.tcag.ca/dgv/app/home/DT
)/)
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
To/TO
experimentally/RB
verify/RB
the/DT
accuracy/NN
of/IN
the/DT
CNV/NN
,/,
we/PRP
performed/VBD
quantitative/JJ
PCR/NN
./.
====================
The/DT
position/NN
of/IN
the/DT
CNV/NN
probe/NN
was/VBD
defined/VBN
based/VBN
on/IN
hg19/NCBI/NN
build/JJ
37/CD
./.
====================
The/DT
probe/NN
ID/NN
used/VBN
for/IN
the/DT
TaqMan/NN
genotyping/VBG
assay/NN
of/IN
the/DT
validated/JJ
CNVs/NNS
is/VBZ
listed/VBN
in/IN
Table/JJ
3/CD
./.
====================
Applications/NNS
of/IN
a/DT
positive/JJ
predictive/JJ
value/NN
as/IN
a/DT
measurement/JJ
standard/JJ
of/IN
accuracy/NN
indicated/VBD
the/DT
proportion/NN
of/IN
positive/JJ
results/NNS
in/IN
the/DT
validation/NN
of/IN
the/DT
CNV/NN
region/NN
./.
====================
The/DT
positive/JJ
predictive/JJ
value/NN
of/IN
the/DT
verified/VBN
CNV/NN
region/NN
evaluated/VBD
in/IN
our/PRP$
validation/NN
was/VBD
0.82/CD
./.
====================
Fig/NN
./.
====================
1/CD
shows/VBZ
the/DT
genotype/NN
of/IN
the/DT
identified/VBN
CNV/NN
region/NN
,/,
verified/VBN
by/IN
quantitative/JJ
PCR/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
performed/VBD
a/DT
GWAS/JJ
to/TO
investigate/VB
the/DT
associations/NNS
between/IN
identified/VBN
CNV/NN
regions/NNS
and/CC
the/DT
risk/NN
of/IN
OF/IN
./.
====================
A/DT
total/JJ
of/IN
eight/CD
CNV/NN
loci/NNS
were/VBD
identified/VBN
to/TO
be/VB
nominally/RB
associated/VBN
with/IN
OF/IN
./.
====================
For/IN
validation/NN
,/,
we/PRP
selected/VBD
one/CD
CNV/NN
region/NN
based/VBN
on/IN
position/NN
and/CC
expected/VBN
biological/JJ
meaning/VBG
among/IN
the/DT
eight/CD
loci/NNS
./.
====================
The/DT
CNV/NN
,/,
which/WDT
is/VBZ
located/JJ
on/IN
chromosome/NN
20q13.12/NN
(/(
intergenic/JJ
region/NN
near/JJ
LINC01260/NN
)/)
was/VBD
experimentally/RB
validated/JJ
through/IN
quantitative/JJ
PCR/NN
./.
====================
An/DT
lncRNA/JJ
is/VBZ
defined/VBN
as/IN
a/DT
non-coding/JJ
transcript/NN
having/VBG
a/DT
length/NN
of/IN
more/RBR
than/IN
200/CD
nucleotides/NNS
[/(
26/CD
]/)
and/CC
is/VBZ
considered/VBN
“/CD
junk/NN
”/CD
that/DT
is/VBZ
non-functional/JJ
initially/RB
[/(
27/CD
]/)
./.
====================
However/RB
,/,
the/DT
functional/JJ
roles/NNS
of/IN
lncRNAs/NNS
have/VBP
now/RB
been/VBN
identified/VBN
,/,
such/JJ
as/IN
key/JJ
regulators/NNS
of/IN
transcriptional/JJ
and/CC
translational/JJ
products/NNS
that/IN
affect/VBP
cell/NN
functions/NNS
[/(
28293031/CD
]/)
./.
====================
lncRNAs/NNS
play/VBP
a/DT
role/NN
in/IN
epigenetic/JJ
effects/NNS
,/,
such/JJ
as/IN
histone/NN
modification/NN
(/(
e.g./FW
,/,
methylation/NN
)/)
,/,
which/WDT
regulates/VBZ
gene/NN
expression/NN
[/(
32/CD
]/)
./.
====================
A/DT
significant/JJ
histone/NN
modification/NN
,/,
monomethylation/NN
of/IN
lysine/NN
4/CD
on/IN
histone/NN
H3/NN
(/(
H3K4me1/NN
)/)
in/IN
human/JJ
mammary/JJ
epithelial/JJ
cells/NNS
,/,
was/VBD
predicted/VBN
in/IN
our/PRP$
identified/VBN
CNV/NN
region/NN
near/JJ
an/DT
lncRNA/JJ
,/,
LINC01260/NN
,/,
using/VBG
University/JJ
of/IN
California/NN
Santa/NN
Cruz/NN
(/(
UCSC/NN
)/)
Genome/NN
Browser/NN
(/(
http/NN
:/:
//genome.uscs.edu/cgi-bin/hgGateway/NN
)/)
(/(
Supplementary/JJ
Fig/NN
./.
====================
4/CD
)/)
./.
====================
A/DT
previous/JJ
genome-wide/NN
study/NN
has/VBZ
identified/VBN
several/JJ
runs/NNS
of/IN
homozygosity/NN
(/(
ROHs/NNS
)/)
associated/VBN
with/IN
BMD/NN
and/CC
observed/VBN
the/DT
enrichment/JJ
of/IN
H3K4me1/NN
in/IN
two/CD
ROHs/NNS
,/,
ROH15q22.3/NN
and/CC
ROH1p31.1/NN
,/,
by/IN
an/DT
analysis/NN
of/IN
histone/NN
modification/NN
marks/VBZ
in/IN
the/DT
Gm12878/NN
cell/NN
line/NN
[/(
33/CD
]/)
./.
====================
Taken/VBN
together/RB
,/,
our/PRP$
identified/VBN
CNV/NN
region/NN
on/IN
20q13.12/NN
might/MD
have/VBP
a/DT
putative/JJ
effect/NN
on/IN
the/DT
risk/NN
of/IN
OF/IN
by/IN
histone/NN
modification/NN
of/IN
the/DT
promoter/NN
region/NN
of/IN
LINC01260/NN
./.
====================
In/IN
addition/NN
,/,
a/DT
CNV/NN
on/IN
chromosome/NN
20q13.12/NN
is/VBZ
located/JJ
in/IN
a/DT
region/NN
about/RB
35/CD
kb/NN
apart/VBP
from/IN
the/DT
WISP2/NN
gene/NN
./.
====================
The/DT
WISP2/NN
gene/NN
has/VBZ
some/DT
evidence/NN
of/IN
functions/NNS
associated/VBN
with/IN
bone-related/JJ
traits/VBZ
./.
====================
WISP2/NN
,/,
also/RB
known/VBN
as/IN
CCN/NN
family/NN
member/NN
5/CD
(/(
CCN5/NN
)/)
or/CC
connective/JJ
tissue/NN
growth/NN
factor/NN
like/IN
(/(
CTGF-L/NN
)/)
,/,
was/VBD
identified/VBN
as/IN
a/DT
member/NN
of/IN
the/DT
CCN/NN
family/NN
,/,
downstream/RB
of/IN
the/DT
WNT–β-catenin/NN
signaling/VBG
pathway/NN
,/,
using/VBG
subtractive/JJ
hybridization/NN
between/IN
WNT1-transformed/JJ
mammary/JJ
epithelial/JJ
cells/NNS
and/CC
parental/JJ
cells/NNS
[/(
34/CD
]/)
./.
====================
The/DT
WNT–β-catenin/NN
signaling/NN
pathway/NN
has/VBZ
been/VBN
suggested/VBN
to/TO
be/VB
a/DT
major/JJ
component/NN
in/IN
the/DT
accrual/JJ
,/,
regulation/NN
,/,
and/CC
maintenance/NN
of/IN
bone/NN
mass/NN
[/(
35/CD
]/)
./.
====================
WISP2/NN
consists/VBZ
of/IN
3/CD
domains/NNS
:/:
an/DT
insulin-like/JJ
growth/NN
factor/NN
binding/NN
domain/NN
,/,
a/DT
von/NN
Willebrand/NN
Factor/NN
type/NN
C/NN
motif/NN
,/,
and/CC
a/DT
thrombospondin/NN
type/NN
I/CD
repeat/NN
./.
====================
The/DT
mRNA/NN
of/IN
WISP2/NN
is/VBZ
expressed/VBN
in/IN
primary/JJ
human/JJ
osteoblasts/NNS
,/,
fibroblasts/NNS
,/,
ovary/NN
,/,
testes/VBZ
,/,
and/CC
heart/NN
./.
====================
WISP2/NN
protein/NN
is/VBZ
secreted/VBN
from/IN
primary/JJ
human/JJ
osteoblasts/NNS
and/CC
fibroblasts/NNS
[/(
36/CD
]/)
./.
====================
A/DT
previous/JJ
study/NN
has/VBZ
shown/VBN
the/DT
relatedness/NN
of/IN
increased/VBN
mRNA/NN
expression/NN
of/IN
WISP2/NN
with/IN
rheumatoid/JJ
arthritis/NN
and/CC
osteoarthritis/NN
[/(
34/CD
]/)
./.
====================
Furthermore/RB
,/,
the/DT
WISP2/NN
gene/NN
has/VBZ
been/VBN
reported/VBN
as/IN
a/DT
candidate/NN
gene/NN
that/WDT
is/VBZ
associated/VBN
with/IN
an/DT
OF-related/JJ
trait/VBP
,/,
BMD/NN
[/(
37/CD
]/)
./.
====================
WISP2/NN
expression/NN
is/VBZ
affected/VBN
by/IN
the/DT
action/NN
of/IN
LRP5/NN
./.
====================
LRP5/NN
has/VBZ
been/VBN
known/VBN
to/TO
play/VB
a/DT
role/NN
in/IN
signaling/VBG
through/IN
WNT–β-catenin/NN
and/CC
acts/VBZ
as/IN
a/DT
co-receptor/NN
with/IN
the/DT
frizzled/JJ
family/NN
of/IN
receptors/NNS
[/(
38/CD
]/)
./.
====================
Previous/JJ
research/NN
has/VBZ
reported/VBN
that/IN
the/DT
LRP5/NN
mutation/NN
(/(
G171V/NN
)/)
,/,
inducing/VBG
the/DT
enhancement/NN
of/IN
structural/JJ
strength/NN
and/CC
material/JJ
properties/NNS
of/IN
skeleton/JJ
and/CC
bone/NN
mass/NN
,/,
is/VBZ
correlated/VBN
with/IN
increased/VBN
expression/NN
of/IN
WISP2/NN
[/(
38/CD
]/)
./.
====================
Also/RB
,/,
WISP2/NN
is/VBZ
suggested/VBN
to/TO
be/VB
involved/VBN
in/IN
the/DT
frizzled/JJ
receptors/LRP5/6/NN
pathway/NN
by/IN
phosphorylation/NN
of/IN
LRP5/NN
[/(
39/CD
]/)
./.
====================
Considering/VBG
the/DT
previously/RB
reported/VBD
functions/NNS
and/CC
interactions/NNS
with/IN
LRP5/NN
in/IN
the/DT
WNT–β-catenin/NN
signaling/NN
pathway/NN
,/,
WISP2/NN
could/MD
be/VB
an/DT
important/JJ
component/NN
for/IN
bone/NN
formation/NN
or/CC
strength/NN
,/,
which/WDT
might/MD
affect/VB
the/DT
risk/NN
of/IN
OF/IN
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
identified/VBD
a/DT
total/JJ
of/IN
8/CD
CNV/NN
regions/NNS
associated/VBN
with/IN
OF/IN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
Among/IN
the/DT
8/CD
CNVs/NNS
,/,
one/CD
locus/NN
,/,
located/JJ
on/IN
chromosome/NN
20q13.12/NN
,/,
was/VBD
selected/VBN
for/IN
validation/NN
and/CC
verified/VBN
by/IN
quantitative/JJ
PCR/NN
./.
====================
Although/IN
further/JJ
study/NN
in/IN
a/DT
larger/RBR
number/NN
of/IN
study/NN
subjects/NNS
is/VBZ
needed/VBN
,/,
to/TO
our/PRP$
knowledge/NN
,/,
the/DT
current/JJ
report/NN
is/VBZ
the/DT
first/JJ
to/TO
investigate/VB
the/DT
association/NN
with/IN
the/DT
risk/NN
of/IN
OF/IN
./.
====================
Our/PRP$
findings/NNS
from/IN
this/DT
study/NN
could/MD
provide/VB
new/JJ
insights/NNS
into/IN
the/DT
genetic/JJ
factors/NNS
associated/VBN
with/IN
OF/IN
risk/NN
./.
====================
Validated/JJ
genotypes/NNS
of/IN
a/DT
20q13.12/NN
copy/NN
number/NN
variation/NN
(/(
CNV/NN
)/)
region/NN
in/IN
this/DT
study/NN
./.
====================
Genotypes/NNS
of/IN
a/DT
CNV/NN
region/NN
on/IN
chromosome/NN
20q13.12/NN
./.
====================
The/DT
copy/NN
number/NN
state/NN
of/IN
cases/NNS
(/(
left/NN
)/)
and/CC
control/NN
samples/NNS
(/(
right/JJ
)/)
./.
====================
The/DT
higher/JJR
bar/JJ
,/,
lower/JJR
bar/JJ
,/,
and/CC
no/DT
bar/JJ
in/IN
each/DT
figure/NN
represent/JJ
a/DT
normal/JJ
number/NN
of/IN
copies/NNS
,/,
heterozygous/JJ
deletion/NN
,/,
and/CC
homozygous/JJ
deletion/NN
,/,
respectively/RB
./.
====================
The/DT
blue/JJ
bar/JJ
means/NNS
the/DT
copy/NN
number/NN
state/NN
of/IN
the/DT
NA10851/NN
sample/NN
,/,
which/WDT
was/VBD
used/VBN
as/IN
the/DT
reference/NN
sample/NN
./.
====================
Clinical/JJ
characteristics/NNS
of/IN
study/NN
subjects/NNS
====================
Association/NN
results/NNS
of/IN
8/CD
CNV/NN
regions/NNS
with/IN
risk/NN
of/IN
OF/IN
(/(
p/NN
</JJR
0.05/CD
)/)
====================
Results/NNS
of/IN
CNV/NN
validation/NN
though/IN
TaqMan/NN
copy/NN
number/NN
assays/NNS
====================
